Global Alzheimers and Parkinsons Diseases Market Size By Type (Alzheimers, Parkinsons), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Alzheimer's and Parkinson's Diseases Market was valued at USD 10.4 billion in 2023 and is projected to reach USD 18.1 billion by 2031, expanding at a CAGR of 7.1% during the forecast period from 2023 to 2031. Growth in this market is primarily driven by the rising prevalence of neurodegenerative disorders, increasing geriatric population, and continuous advancements in diagnostic and therapeutic technologies. Additionally, heightened awareness and early diagnosis, coupled with robust investments in R&D for disease-modifying treatments, are bolstering market expansion globally.

Drivers

1. Rising Geriatric Population

An aging global population is significantly contributing to the rising incidence of Alzheimer's and Parkinson's diseases. As age is a primary risk factor, countries with rapidly growing elderly populations are witnessing higher prevalence rates, thereby fueling market demand for diagnostics and therapeutics.

2. Advancements in Diagnostic and Therapeutic Technologies

Continuous innovation in imaging techniques, biomarkers, and precision medicine has improved early detection and monitoring. Novel drug delivery systems and emerging therapies—like monoclonal antibodies and gene therapy—are reshaping treatment landscapes.

3. Increased Research Funding and Collaborations

Public and private funding into neuroscience research has escalated. Strategic alliances between academic institutions, biotech firms, and pharmaceutical companies are accelerating drug development pipelines.

Restraints

1. High Cost of Treatment and Diagnostics

The expenses associated with neuroimaging, biomarker tests, and long-term care of patients are substantial. These costs pose a challenge in developing and underinsured regions.

2. Limited Efficacy of Current Therapies

Most existing therapies focus on symptomatic relief rather than halting or reversing disease progression. This unmet need continues to limit treatment satisfaction and clinical outcomes.

Opportunity

1. Emergence of Disease-Modifying Therapies

Promising developments in disease-modifying agents—especially for Alzheimer's—are expected to redefine the market. With several candidates in late-stage trials, successful approvals can unlock significant commercial opportunities.

2. Expansion in Emerging Markets

Rising healthcare infrastructure and diagnostic capabilities in countries across Asia-Pacific, Latin America, and the Middle East offer untapped growth potential for pharmaceutical companies targeting neurodegenerative diseases.

Market by System Type Insights

The Therapeutic Segment accounted for the largest share in 2023, driven by high demand for symptomatic treatment options including cholinesterase inhibitors and dopamine agonists. Meanwhile, the Diagnostic Segment is expected to grow at the fastest pace, supported by increased deployment of PET/MRI imaging and fluid biomarkers for early-stage detection and disease progression tracking.

Market by End-use Insights

In terms of end-use, Hospitals & Specialty Clinics dominated the market in 2023 due to their ability to provide comprehensive neurological care. Home Care Settings are projected to witness notable growth, influenced by a rising preference for outpatient treatment and improved at-home monitoring tools, especially for patients in advanced stages of disease.

Market by Regional Insights

North America led the market in 2023, supported by strong healthcare infrastructure, widespread awareness, and ongoing clinical trials. However, the Asia-Pacific region is anticipated to register the highest growth rate, fueled by an aging population, rising healthcare investments, and increasing diagnosis rates in countries like China and Japan.

Competitive Scenario

Key players in the global Alzheimer's and Parkinson's Diseases Market include Biogen Inc., Eisai Co., Ltd., AbbVie Inc., Roche Holding AG, Novartis AG, Eli Lilly and Company, UCB S.A., Teva Pharmaceutical Industries Ltd., AC Immune SA, and Amneal Pharmaceuticals Inc. These companies are heavily focused on research and development, strategic partnerships, and regulatory approvals for advanced therapies targeting neurodegenerative disorders.

Scope of Work – Global Alzheimer's and Parkinson's Diseases Market

Report Metric Details

Market Size (2023) USD 10.4 billion

Projected Market Size (2031) USD 18.1 billion

CAGR (2023–2031) 7.1%

Market Segments By System Type (Therapeutics, Diagnostics), By End-use (Hospitals & Clinics, Home Care, Research Institutes)

Growth Drivers Rising aging population, Advances in diagnostics and therapy, Increased R&D funding

Opportunities Disease-modifying drugs, Growth in emerging healthcare markets

Key Market Developments

2023: Biogen and Eisai secured FDA accelerated approval for lecanemab, a novel anti-amyloid Alzheimer’s treatment.

2024: Roche expanded its clinical trial pipeline for Parkinson’s therapies focused on α-synuclein aggregation inhibitors.

2025: Eli Lilly initiated a large-scale global trial for donanemab targeting early Alzheimer’s patients, aiming at full regulatory approval by 2026.

FAQs

1) What is the current market size of the Global Alzheimer's and Parkinson's Diseases Market?

The market was valued at USD 10.4 billion in 2023.

2) What is the major growth driver of the Global Alzheimer's and Parkinson's Diseases Market?

The primary growth driver is the rising global geriatric population, which sig